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Abstract
SomaticSeq is an accurate somatic mutation detection pipeline implementing a stochastic boosting algorithm to
produce highly accurate somatic mutation calls for both single nucleotide variants and small insertions and deletions.
The workflow currently incorporates five state-of-the-art somatic mutation callers, and extracts over 70 individual
genomic and sequencing features for each candidate site. A training set is provided to an adaptively boosted decision
tree learner to create a classifier for predicting mutation statuses. We validate our results with both synthetic and real
data. We report that SomaticSeq is able to achieve better overall accuracy than any individual tool incorporated.
Background
Cancers are diseases of the genome. Somatic single
nucleotide variants (SNVs) and small insertions and dele-
tions (indels) are common drivers of carcinogenesis.
Therefore, accurately detecting somatic mutations is a
key analysis in cancer research. The challenge and com-
plexity of cancer sequencing analysis lie in the hetero-
geneous nature of tumor samples, in addition to the
cross-contamination between tumor andmatched normal
samples.
A somatic tool that performs well for one tumor may
perform poorly for another, as reported in a number
of comparative studies [1, 2]. For instance, MuTect is a
somatic SNV caller that applies a Bayesian classifier to
detect somatic mutations [3]. It is sensitive in detect-
ing low variant allele frequency (VAF) somatic variants.
It also incorporates a series of filters to penalize can-
didate variants that have characteristics corresponding
to sequencing artifacts to increase precision. However,
MuTect applies severe penalties to somatic variant candi-
dates if the variant reads are also found in the matched
normal. While this approach filters out most germline
variant false positives, it adversely affects sensitivity in
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some cancer types where it is not possible to obtain a clean
normal sample, e.g., liquid cancers.
SomaticSniper was developed with the aforementioned
issue in mind [4]. It applies a Bayesian model to detect
genotype change between the normal and tumor tis-
sues, taking into account the prior probability of somatic
mutation. Thus, it is far more tolerant of impure normal
samples at the expense of calling a lot more germline vari-
ants as somatic. It is also less sensitive toward low VAF
mutations. Another Bayesian approach is JointSNVMix2,
which jointly analyses paired tumor–normal digital allelic
count data [5]. It has very high sensitivity inmany different
settings, but tends to be lower in precision.
A different statistical approach is using Fisher’s exact
test (FET) to detect genotype change, such as VarScan2
and VarDict. VarScan2 reads data from both tumor and
normal samples simultaneously and classifies sequence
variants by somatic status [6]. At high enough sequencing
depth, even a slight change in VAF between the normal
and tumor may result in statistical significance by FET,
thus calling many germline variants as somatic mutations.
On the other hand, VarScan2 will not miss clear mutations
due to situation-specific filters that may not appropriately
apply in all situations. VarDict is specifically designed to
detect important but challenging variants that tend to be
missed or ignored by other callers. It applies a series of
false positive filters to increase precision [7]. It can handle
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ultra-deep sequencing with depth up to hundreds of thou-
sands, where most algorithms would either fail or perform
poorly.
Given the unique characteristics of each algorithm,
integrating them is often desirable to ensure muta-
tions are comprehensively captured [8–10]. On the other
hand, combining the false positives from all the differ-
ent algorithms can easily overwhelm the results. Accu-
rately distinguishing true somatic mutations from the
false positives is thus essential in accurate interpretation.
Simple rule-based filters can often remove the major-
ity of false positives due to sequencing artifacts, e.g.,
Database of Single-Nucleotide Polymorphisms (dbSNP)
sites, extreme strand bias, nearby homopolymers, low
mapping quality, proximity to end of reads, proximity
to indels, and extremely low or high read depth [4, 6].
However, hard filters also significantly reduce the sensitiv-
ity and permanently remove certain mutations from ever
being detected due to their locations within the genome.
Previously, Kim et al. built a combined caller using logistic
regression with a feature-weighted linear stacking (FWLS)
model to improve somatic SNV prediction accuracy [11].
The model considers the degree of consensus of three
callers in addition to a series of associated features. It cal-
culates a probability value (0 ≤ P ≤ 1) for each mutation
candidate; however, which cut-off value to choose is not
always obvious. Since the study did not perform somatic
indel analysis, its performance on non-substitution vari-
ants is unclear.
To address these aforementioned problems, we pro-
pose SomaticSeq. It implements a machine-learning algo-
rithm that accurately identifies both somatic SNVs and
indels from tumor–normal pairs. It maximizes its sensi-
tivity by combining SNV calls from the five previously
described algorithms that complement each other, i.e.,
MuTect, SomaticSniper, VarScan2, JointSNVMix2, and
VarDict. It combines somatic indel calls from Indelocator
[12], VarScan2, and VarDict. For each mutation call, we
generate up to 72 features by SAMtools, HaplotypeCaller,
and the callers themselves. We have implemented the
Adaptive Boosting model in R using the ada package [13],
which constructs a classifier consisting of an ensemble of
decision trees from a training set. The classifier is then
applied to a target set to yield a probability (P) of a true
positive for each somatic variant call.
In this study, we have chosen an optimal P (≥0.7) as
the probability cut-off value for all of our analyses based
on the results from the International Cancer Genome
Consortium (ICGC) – The Cancer GenomeAtlas (TCGA)
Dialogue for Reverse Engineering Assessments and
Methods (DREAM) Challenge given in “Results”. One
advantage of the stochastic boosting model over FWLS
is that the overall accuracy is not sensitive to the choice
of P over a wide range of values as shown in our results.
We have validated SomaticSeq with a variety of synthetic
and real tumor data and have achieved high accuracy
in the most challenging situations. We use F1 score, the
harmonic mean of precision and sensitivity,
F1 = 2 × sensitivity × precisionsensitivity + precision ,
as a measure of overall accuracy. Sensitivity is defined as
true positive rate (aka recall) and precision as positive pre-
dictive value. A schematic of the SomaticSeq workflow is
illustrated in Fig. 1.
Availability and implementation
The SomaticSeq website [14] is regularly updated with
improvements, and also includes links to the source
code, releases, and data. The source code for Somatic-
Seq is deposited and maintained at [15] under a Berkeley
Software Distribution (BSD) open-source license. We
used SomaticSeq 1.0 [16] for all the analyses in this paper.
Fig. 1 SomaticSeq workflow. The workflow starts with FASTQ files for both the tumor and the matched normal sequencing reads, which are
processed using Genome Analysis Toolkit (GATK) best practices to create two BAM files. The five somatic SNV callers (and three indel callers) are run
on the pair of BAM files to generate mutation calls. Their results are merged, and then up to 72 features for each of the combined calls are generated
from the BAM files using SAMtools and GATK HaplotypeCaller, as well as outputs from the callers themselves. The ensemble along with the feature
set is then provided to the machine-learning model, which is trained with either a separate data set or a portion of these data. After training, the
model calculates the probability for each call, yielding a high-confidence somatic mutation call set
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SomaticSeq was developed in the Python and Bash
scripting languages and can utilize the available hardware
parallelism to achieve the best performance. The indi-
vidual somatic mutation callers are invoked in a region
parallel fashion to achieve an efficient run time for the
most performance-critical step. Furthermore, Somatic-
Seq can make use of an available Sun Grid Engine (SGE)
cluster to scale performance beyond one hardware node.
Since the users may want to run the individual callers
with different parameters, SomaticSeq provides the flex-
ibility of configuring the command-line options for these
tools. We also emphasize that the machine-learning train-
ing component of SomaticSeq has relatively low resource
requirements when compared to running the callers. In
fact, for the DREAM Challenge data set, which had 30×
coverage, it took around 3 hours to train the classifier
and used a maximum of 20 GB of memory. Since train-
ing is only done once, this is a one-time cost to incur. The
trained classifier is typically 1 GB in size and the predic-
tion step using it only took around an hour per DREAM
Challenge data set. Thus, apart from the resource require-
ments and time to run the individual callers, SomaticSeq
incurs little overhead. Finally, the flexibility and perfor-
mance efficiency make SomaticSeq an extremely useful
software resource for cancer researchers. The data used in
this study are available via the links in Additional file 1 and
at the SomaticSeq website [17].
Results
We used a variety of real and synthetic data sets to validate
SomaticSeq, including the ICGC-TCGADREAMSomatic
Mutation Calling Challenge, in silico titration, Somatic-
Spike, and real tumor–normal pairs. The data sets used
for each procedure are summarized in Additional file 1:
Table S1.
ICGC-TCGA DREAM Somatic Mutation Calling Challenge
First, we present SomaticSeq’s performance on tumor–
normal data produced by the ICGC-TCGA DREAM
Somatic Mutation Calling Challenge (the DREAM Chal-
lenge) [18]. The DREAM Challenge is a community effort
to improve bioinformatics algorithms, and in this case
somatic mutation detection accuracy. It uses BAMSur-
geon to spike mutations computationally into a healthy
genome to create synthetic but realistic tumor–normal
pairs. The ground truth of the in silico somatic muta-
tions are made public after the challenge deadline. The
sequencing depths for both the tumor and normal
genomes are approximately 30×. Thus, at low VAFs or in
low-coverage regions, there may not be any evidence in
the data supporting a mutation. While the somatic muta-
tions in these data are synthetic, the rest of the genome
is real, containing actual experimental artifacts associated
with sequencing technologies and sample preparations
that give rise to false positives. The current limitation
for using real tumor–normal sequencing data for bench-
marking is the lack of ground truth. Thus, the DREAM
Challenge is an excellent source of unbiased data for
validation.
There are successive stages of the DREAM Challenge,
which increase in data complexity, e.g., multiple subclonal
populations and simulated contamination to create data
sets that are more challenging. The results presented in
this study are based on Stage 3, the most complex pub-
lishable stage to date. We used a modified data set from a
previous stage as the training set for SomaticSeq. Namely,
we mixed the tumor and normal data from Stage 2 (no
contamination) at 70 : 30 ratio to create a tumor con-
tamination profile. SomaticSeq found two distinct clusters
of calls with different probability values (Fig. 2a, b). The
exact accuracy (F1 score) depended on the choice of cut-
off for P. Given that the F1 score was stable over a wide
range of P, we used a value of 0.7 throughout the study,
which slightly favored precision over sensitivity (Fig. 2).
Mixing of normal reads into the tumor in Stage 2 data
improved the overall accuracy compared to using Stage 2
data directly (data not shown), indicating the importance
of having a training set with characteristics similar to
those of the target set. The SomaticSeq results presented
here were averaged over ten cross-validation results (the
training set consists of half of the entire data set, ran-
domly chosen). We performed twofold cross-validation
ten times instead of the more common tenfold validation
(using 90 % of the data for training) because in some cases
choosing 90 % of the data for training would leave too little
data for validation. The DREAM Challenge has a perma-
nent website [19], where the data set for each challenge,
including the somatic mutations described here, can be
downloaded.
Cross-contamination is a major challenge in real can-
cer sequencing. Pure tumor or pure normal samples are
often impossible to obtain. To evaluate SomaticSeq’s per-
formance in these challenging butmore realistic situations
better, we created more data sets (Settings) by mixing
the tumor and normal data from the DREAM Challenge
at different ratios to create different cross-contamination
profiles. Setting A was Stage 3 data with no modification,
i.e., no contamination, although the tumor had three dif-
ferent VAFs (50 %, 33 %, and 20 %) representing three
different subclones. In Setting B, we mixed the normal
and tumor data at 95 : 5 ratio to create a normal sam-
ple contaminated with 5 % tumor cells. In Setting C, we
mixed the tumor and normal data at a 70 : 30 ratio to
create a tumor contaminated with 30 % normal cells, so
the tumor VAFs were 35 %, 23 %, and 14 %. Setting D
was the most challenging data set we simulated for the
DREAM Challenge, with the normal from Setting B and
tumor from Setting C, i.e., the tumor and normal samples
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Fig. 2 DREAM Challenge Stage 3 results trained from modified Stage 2 data. a Histogram of probability values (P) of all the mutation candidates in
Stage 3. Higher probability values (closer to 1) imply that calls are more likely true somatic mutations. b The same plot with the y-axis in log10 scale.
The overlaps can be seen. Keep in mind each unit in the y-axis is a tenfold increase. c An accuracy plot showing sensitivity, precision, and F1 scores
vs. P cut-off
were cross-contaminated. The accuracies of SomaticSeq
and the individual tools that it incorporates are shown
in Fig. 3. SomaticSeq vastly outperforms any individual
tool in all situations. For instance, in Setting D, Somat-
icSeq achieved an F1 score of 90.5 % (83.2 % sensitivity
and 99.4 % precision) in SNVs, whereas the best single
tool, MuTect, had an F1 score of 62.4 % (64.8 % sensitivity
and 60.1 % precision). For a more detailed breakdown, see
Additional file 1: Table S2.
In silico titration: accuracy as a function of VAF
We performed insilico titration of NA12878 (Platinum
genome) and NS12911 (HuRef J Craig Venter genome)
to construct partially real tumor–normal pairs of
approximately 50× sequencing depth. We treated
NS12911 as the tumor genome and NA12878 as
the matched normal (Fig. 4). The ground truth was
constructed as illustrated in “Methods” (Fig. 5).
We mixed the two genomes in silico at different ratios
to simulate different cross-contamination profiles, result-
ing in different VAFs for both the tumor and the normal.
Namely, NA12878 and NS12911 were mixed at 0 : 100,
50 : 50, and 70 : 30 ratios to create virtual tumors with
target VAFs of 50 %, 25 %, and 15 %. They were also mixed
at 100 : 0 and 95 : 5 ratios to create a virtual matched nor-
mal. Six in silico tumor–normal pairs were created out of
those three virtual tumors and two virtual normals. The
prior probability of somatic mutation was enforced to be
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Fig. 3 F1 scores of SomaticSeq and the individual tools for the DREAM Challenge Stage 3 cross-validation. On the x-axes, Setting A is the pure
normal/pure tumor. Setting B is the contaminated normal/pure tumor. Setting C is the pure normal/contaminated tumor. Setting D is the
contaminated normal/contaminated tumor. a SNV results. b Indel results
one in a million to make the performance more realistic.
SomaticSeq’s performance for these six settings is shown
in Fig. 6, and there is a detailed breakdown in Additional
file 1: Table S3. The performance of SomaticSeq and each
individual tool in the in silico titration was consistent with
the results from the DREAMChallenge data. For instance,
in Setting N2.5T15, SomaticSeq achieved an F1 score of
80.5 % (68.4 % sensitivity and 97.8 % precision) in SNVs,
whereas the best single tool, VarDict, had an F1 score of
29.6 % (30.7 % sensitivity and 14.3 % precision).
SomaticSpike: accuracy as a function of sequencing depth
SomaticSpike is a method described by Cibulskis et al.
for creating virtual tumors with different VAFs and
sequencing depths [3]. We used it to test SomaticSeq’s
performance. In our SomaticSpike experiment, a pure
genome of NA12878 at 30× was used as the normal sam-
ple. To create virtual tumor samples, reads fromNA12891
having different genotypes from NA12878 were spiked
into the NA12878 genome to create genomes with vir-
tual somatic mutations at those sites. They were spiked at
various proportions to create different VAFs. For tumor
sequencing depths of 10×, 20×, 30×, 40×, and 50×, VAFs
of 0.05, 0.10, 0.20, and 0.40 were created. The prior prob-
ability of somatic mutation was enforced to be one in a
million to make the performance more realistic. The over-
all accuracy (F1 score) of SomaticSeq was expectedly bet-
ter with higher sequencing depth and higher VAF (Fig. 7),
Fig. 4 In silico titration of two human genomes. Blue represents reads from NA12878 (designated normal). Red represents reads from NS12911
(designated tumor). Going from (a) to (b) represents a somatic mutation of G>A, where G in the normal is a homozygous reference and A in the
tumor is a heterozygous variant. c A normal contaminated with tumor tissues. d A tumor sample contaminated with normal tissues
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Fig. 5 Obtaining the ground truth for the in silico tumor–normal data. In the NA12878 and NS12911 mixture, there are a total of 746,280 virtual
somatic SNVs and 64,399 virtual somatic indels. A total of 2.2 billion high-confidence sites are interrogated (the remaining are ignored). During our
analyses, a somatic mutation rate of one out of a million was enforced to represent a realistic prior probability of somatic mutations
and outperformed the individual tools that it incorpo-
rates (see Additional file 1: Tables S4–S8). For instance,
for 50× sequencing coverage with VAF of 20 %, Somatic-
Seq achieved an F1 score of 96.6 % (94.6 % sensitivity and
98.8 % precision), whereas the best single tool, Somatic-
Sniper after having applied the recommended false posi-
tive filter, had an F1 score of 49.0 % (73.6 % sensitivity and
36.7 % precision).
Real tumor–normal pairs
To demonstrate SomaticSeq’s validity on real sequencing
data, we selected two sets of publicly available tumor–
normal pairs with published lists of validated somatic
mutations as a benchmark for our model. COLO-829
is an immortal metastatic malignant melanoma cell line
[20]. The whole-genome sequencing of COLO-829 and
its matched normal blood COLO-829BL have sequenc-
ing depths of 80× and 60×, respectively. There are 454
validated mutations for COLO-829 [21]. CLL1 is whole-
genome sequencing data from a chronic lymphocytic
leukemia patient. The sequencing depths for the CLL1
tumor and normal are 53× and 42×, respectively. There
are 961 published mutations for CLL1 [22]. Since these
data sets only had a subset of knownmutations considered
as true positives, no information with regard to true nega-
tives (i.e., validated as reference bases) was available. Thus,
it was not possible to calculate overall accuracy. In addi-
tion, each sequencing center had an analytical pipeline
that usually incorporates a popular tool to call somatic
mutations. As a result, any validated call was a sub-
set of that particular caller, which would produce 100 %
sensitivity if identical settings were used. Due to this limi-
tation, we could not make unbiased comparisons between
SomaticSeq and individual callers. Nevertheless, we used
the DREAM Challenge Stage 3 data as the training set
for SomaticSeq, and obtained sensitivities of 99.6 % and
89.2 % for COLO-829 and CLL1, respectively (Table 1).
SomaticSeq’s call set sizes were considerably smaller than
those of the individual callers, implying a higher speci-
ficity. The call set sizes and sensitivities also varied little
with respect to the P threshold, consistent with our obser-
vation of synthetic data (Fig. 8).
To determine if there were any systematic differences in
functional annotations of the somatic variants identified
Fig. 6 F1 scores of SomaticSeq and the individual tools in in silico titration. Color legends are shown in Fig. 3. On the x-axes, the subscript denotes
the expected VAF as a percentage, i.e., N0T50 means the normal has VAF = 0 % (i.e., pure normal) and the tumor has VAF = 50%. N2.5T15 represents a
challenging data set where VAF = 2.5 % for normal and VAF = 15 % for tumor, i.e., 5 % of the normal sample is contaminated with tumor tissues and
30 % of the tumor sample is contaminated with normal tissues. a SNV results. b Indel results
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Fig. 7 F1 scores vs. VAF for different coverage depths
as high-confidencemutations (PASS, for P ≥ 0.7) vs. likely
false positives (REJECT, for P ≤ 0.1), the variants were
annotated with combined annotation dependent deple-
tion (CADD) scores [23]. SnpEff v4.0 was used to predict
the effect of each SNV on the translated protein [24, 25].
We found that likely true somatic mutations (PASS) in
both samples were significantly more deleterious than
likely false positives (REJECT) by SomaticSeq (Fig. 9). No
statistical significance was detected between the PASS and
LowQual (for 0.1 < P < 0.7) calls. There were about twice
as many PASS calls and 50 times as many REJECT calls
as there were LowQual calls. Figure 2b shows that a good
number of true somatic mutations can be expected from
LowQual calls.
It is reasonable to assume that because cancers are dis-
eases of the genome, deleterious mutations should be
enriched in somatic mutations versus random chance.
While ground truth was unknown for these data sets, the
difference in CADD scores indicated that SomaticSeq’s
high-confidence call set was enriched with deleterious
variants when compared to the rest of the entire call set.
Discussion
Each somatic mutation caller implements a unique set of
algorithms, with its own assumption of how to discrimi-
nate statistically true somatic mutations from sequencing
noise. However, each cancer sequencing experiment is dif-
ferent due to the complex nature of different tumor types,
and no one algorithm is appropriate for all cancer stud-
ies. While clean tumor–normal pairs may be obtained for
solid tumors like breast cancer, this may not be feasible for
liquid cancers where the samples are far more challeng-
ing, such as leukemia or mesothelioma due to expected
cross-contamination.
In our modified DREAM data and in silico titration,
MuTect performed the best when the normal contained
no tumor contamination (see Additional file 1: Tables S2
and S3). It was by far the most sensitive tool among those
we have tested when the normal was pure and tumor VAF
was very low. On the other hand, it had little tolerance
for any contamination in the normal sample, rendering it
unsuitable for tumor types where the normal sample is
contaminated with tumor cells.
On the other hand, SomaticSniper and VarScan2 look
for changes in variant signal between the normal and
tumor, at the expense of calling a lot more germline vari-
ant false positives. JointSNVMix2, while it over-called
mutations more than the other tools in our benchmark,
maintained a high sensitivity in a variety of settings, mak-
ing it a valuable addition to SomaticSeq.
Table 1 SomaticSeq sensitivity on real data. ≥N tools represents the consensus of at least N callers. The two sets of real tumor–normal
sequencing data were downloaded from the European Genome Archive. SomaticSeq predictions were trained from the DREAM Stage
3 data sets
Sample COLO-829 CLL1
SNV Number of calls Sensitivity Number of calls Sensitivity
MuTect 46,831 0.996 8,361 0.895
VarScan2 64,927 0.987 19,797 0.888
SomaticSniper 53,077 0.996 13,690 0.907
JointSNVMix2 85,983 0.996 22,534 0.899
VarDict 53,076 0.857 5,748 0.883
Union of five tools 191,696 0.998 55,196 0.935
≥2 tools 57,254 0.996 13,594 0.916
≥3 tools 43,848 0.996 5,836 0.904
≥4 tools 38,216 0.996 2,637 0.886
=5 tools 34,086 0.857 1,749 0.842
SomaticSeq 37,452 0.996 2,320 0.892
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Fig. 8 SomaticSeq performance on real data. a The sensitivity of SomaticSeq as a function of P cut-offs. b The call set size as a function of P cut-offs,
normalized to the call set size at P = 0.7, i.e., the ratio between the call set size at a given P and the call set size at P = 0.7 (default cut-off in this study)
VarDict was the best indel detector when the VAF
dipped below 50 %. Additional somatic mutation callers
can also be incorporated into SomaticSeq to improve its
performance further. However, the value of each addi-
tional tool depends on its uniqueness. We aim to incor-
porate unique algorithms capable of detecting challenging
variants missed by others, while the machine-learning
model is excellent at discriminating true mutations from
false positives in the union of call sets.
A simple consensus approach has been used to improve
accuracy [9]. While the accuracies of the consen-
sus approach showed improvement over the individual
callers, they were not as accurate as SomaticSeq. In addi-
tion, the specific combinations of caller consensus were
different depending on the data sets (Additional file 1:
Tables S9–S12).
SomaticSeq is also a flexible framework, such that users
may choose to run fewer tools due to the limitation of
computing resources. In Additional file 1: Tables S13–S15,
we show the performance of SomaticSeq incorporating
any combination of one to five tools (Additional file 1:
Fig. S1). We also show the negative predictive values for
these analyses (Additional file 1: Table S16). The accura-
cies incorporating all five tools are more robust regardless
of the data characteristics. Using the right combination of
fewer tools in some situations can achieve equally good
results, but the optimal combination is not the same for
every data set.
Users may also opt to simplify the model by using only
the most important features. In Additional file 1: Table
S17 and Additional file 1: Fig. S2, we have shown the accu-
racies of SomaticSeq with the top five, ten, and 20, and full
feature sets. The improvement in accuracies is the most
pronounced between using only five and ten features, and
has diminishing returns as the feature set increases in
size. Nevertheless, maximum robustness and accuracy are
Fig. 9 CADD scores from SomaticSeq’s PASS (high confidence) calls vs. LowQual (medium confidence) vs. REJECT (likely false positive) calls.
a COLO-829. b CLL1. Only non-synonymous SNVs were evaluated. The p-values were calculated from a two-sided Wilcoxon rank-sum test
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achieved with the full feature set. We discuss the feature
sets in more detail in “Methods”.
We have shown that SomaticSeq is excellent at remov-
ing false positives from a call set. However, it relies on
the tools we have incorporated to obtain a call set, thus
its sensitivity is limited by the individual tools. In its cur-
rent implementation, all the tools incorporated into the
SomaticSeq workflow rely on short read alignment to
detect somatic mutation candidates. Thus, it has difficulty
detecting mutations that occur in low mappability, ultra-
high coverage, low complexity, or otherwise difficult-to-
align regions.
For our future work, we may add multi-sample func-
tionality to our approach by incorporating algorithms
such as multiSNV, which takes multiple tumor sam-
ples from the same patients to take advantage of evo-
lution modeling in heterogeneous cancers to increase
the sensitivity and specificity of somatic mutation detec-
tion [26]. The tools we have currently implemented
assume there is only a single tumor–normal pair.
With five such tools incorporated in the workflow,
SomaticSeq has been shown to be a highly accurate
somatic SNV and indel detector for all types of tumor–
normal data.
Conclusions
SomaticSeq is a flexible, comprehensive, and automated
pipeline that incorporates the strengths of different
somatic mutation detection algorithms. Components in
our pipeline (e.g., aligners, somatic callers, and training
features) can be substituted to best suit the needs of the
user. It will perform best if the characteristics of the train-
ing set are similar to those of the target set. Nevertheless,
SomaticSeq provides a default trained model from high-
quality synthetic data with which we have demonstrated
its high accuracy and robustness.
Methods
Somatic mutation callers
While many individual callers have optional input param-
eters that can improve prediction results for sequencing
data of different characteristics (e.g., ploidy, purity, muta-
tion rate, etc.), those parameters are usually unknown
to researchers. Thus, in most cases, we used default or
recommended settings for each caller. For MuTect, we
supplied dbSNP version 138 [27], Catalogue of Somatic
Mutations in Cancer (COSMIC) version 69 [28], and a
panel of normal based on Phase 1 of the 1000 Genomes
Project as resource files for the real sequencing data.
We did not supply COSMIC for the DREAM Challenge,
because the synthetic mutations were randomly chosen
and were not enriched in COSMIC sites. In our in sil-
ico titration and SomaticSpike experiments, none of these
databases was used.
For SomaticSniper, we used a mapping quality cut-off of
25, a base quality cut-off of 15, and a prior somatic muta-
tion probability of 10−4. For VarScan2, we used a mapping
quality cut-off of 25 and a base quality cut-off of 20. For
JointSNVMix2, we used a convergence threshold of 0.01
in training, and only considered calls with a somatic prob-
ability ≥0.95. For VarDict, we relaxed some built-in filters
to increase its sensitivity (at the expense of precision).
Specifically, we relaxed the variant depth filter from 4 to 2,
and the FET p-value cut-off from 0.05 to 0.15. In addition,
we allowed each call to fail for up to two out of 20 VarDict
filters.
These parameters were chosen from our experiences
with Stage 3 of the DREAM Challenge. Except for the dif-
ferent resource files we have supplied to MuTect, we used
the same configuration for all of our analyses presented in
this study.
SomaticSeq workflow
The complete SomaticSeq workflow is illustrated in Fig. 1.
From the raw sequencing reads, BAM files for the normal
and tumor sequencing reads are generated using GATK
best practices [29]. From the tumor–normal BAM files,
a union of somatic SNVs is called from MuTect, Somat-
icSniper, VarScan2, JointSNVMix2, and VarDict. Somatic
indels are called from VarScan2, VarDict, and Indelocator
(aka SomaticIndelDetector). For each of themutation can-
didate positions, we integrate and standardize the feature
sets. We use SAMtools [30] and GATK HaplotypeCaller
on the tumor and normal BAM files to obtain a number
of independent sequencing features that have predictive
values for their somatic mutation statuses, e.g., mapping
quality, base call quality, strand bias, depth of coverage,
tail distance bias, etc. Some caller features, e.g., somatic
mutation scores based on its distinct statistics, are also
included. For the DREAM Challenge and real data, we
also consider whether the site is in dbSNP. Two of the
most important features in the adaptively boosted classi-
fiers include the root-mean-square mapping quality score
and the number of read mismatches compared to the
reference. Histograms visualizing some of the features’
predictive values are shown in Additional file 1: Fig. S3.
We use the R package ada to train the stochastic boost-
ing machine-learning algorithm in SomaticSeq [13]. The
stochastic boosting learner constructs a classifier con-
sisting of a sequence of decision trees based on up to
72 genomic and sequencing features to discriminate true
somatic mutations in the training set. The constructed
classifier is then applied to a target set, and calculates the
probability of each candidate site being a true somatic
mutation (Fig. 2). Some of those features are stronger pre-
dictors than others, but they all add some value to the
model. When all features are combined, the model is very
accurate. For the results described in this study, we have
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used P ≥ 0.7 as the cut-off for our SomaticSeq results,
i.e., a candidate site of P ≥ 0.7 is considered a PASS
call, whereas a candidate site of P < 0.7 is considered
LowQual. The cut-off value of 0.7 is chosen to prioritize
slightly precision over sensitivity, though the actual accu-
racies tend to be very robust to a wide range of values
(Fig. 2).
Trainedmodels
The importance of each feature differs from data set to
data set, but there is a lot of overlap for the most impor-
tant features. In all settings of the DREAMChallenge SNV
data, 18 of the top 20 features overlapped. They are listed
as follows (not ranked):
• Classification by MuTect (binary values of 0 or 1)
• Classification by JointSNVMix2
• Classification by SomaticSniper
• Classification by VarDict
• FET somatic p-value reported by VarDict
• Average mapping quality in the tumor BAM file
• Average mapping quality in the normal BAM file
• Forward and reverse read counts supporting a variant
in tumor
• Forward and reverse read counts supporting a
reference in tumor
• Forward and reverse read counts supporting a
reference in normal
• Read depth in tumor
• Read depth in normal
• Number of mismatches (compared to reference) in
tumor reads
• dbSNP membership (binary values of 0 or 1)
• Strand bias odds ratio reported by VarDict
Four of the top 18 features were simple classifications
made by the individual tools (whether or not the caller has
called it a somatic mutation). The only caller classifica-
tion not on the list was VarScan2, although it was outside
the top 20 only in Setting D. For Settings A, B, and C, the
VarScan2 classification was ranked number 16, 20, and
17, respectively. Because VarScan2 has a series of (tun-
able) filters prior to evaluations, e.g., a minimum VAF of
10 % and minimum coverage of 8×, VarScan2’s sensitivity
in challenging data sets like Setting D is reduced. Other
important features are related to the quantity of evidence
(e.g., read counts and read depth), quality of evidence
(read mismatch and mapping qualities), and sequencing
artifacts (strand bias). Prior knowledge (dbSNP member-
ship) was also valuable. Since eight of the top 18 features
related directly to sequencing depth, it is important for
the trained model to have a comparable sequencing depth
as the target set. Thus, it would not be appropriate to use
a 30× whole-genome sequence trained model to predict
somatic mutations in a 500× targeted sequencing, e.g.,
three variant reads in 30× data imply 10 % VAF, but 3
reads in 500× data imply 0.6 % VAF, which is very little
evidence over expected sequencing errors.
A trained model consists of an ensemble of decision
trees with different relative weights. For the model trained
from the combined DREAM Challenge Settings A and B,
which we used to predict real data, the top decision tree
can be described as follows:
if_MuTect < 0.5 -1
VarScan2_Score < 27.5 -1 *
VarScan2_Score >= 27.5 -1
if_dbsnp >= 0.5 -1 *
if_dbsnp < 0.5 1 *
if_MuTect >= 0.5 1
if_VarDict < 0.5 -1 *
if_VarDict >= 0.5 1
if_JointSNVMix2 < 0.5 -1
T_MQ < 59.5 -1 *
T_MQ >= 59.5 1 *
if_JointSNVMix2 >= 0.5 1 *
T_MQ is the root-mean-square mapping quality in the
tumor BAM file. VarScan2_Score is the Phred-scale FET
p-value reported by VarScan2. The asterisks denote ter-
minal nodes. This is the number 1 decision tree from the
trained model we used to predict somatic mutations for
the publicly available data (Table 1). The tree view is pre-
sented in Additional file 1: Fig. S4. This trained model,
along with the indel model trained from the same data set,
can be downloaded from our Git repository [14].
The prediction accuracy of the target set largely depends
on the similarity between the training and target sets.
Thus, ideally, a randomly sampled subset of the same
data is used for training as described by Kim et al., e.g.,
randomly choose 500–1000 mutation candidates from
a large sequencing study for validation sequencing, to
construct a training set with hundreds of true somatic
mutations and confirmed true negatives [11]. It is impor-
tant to keep the training and target sets similar in terms
of sequencing depth, platforms, and identical data pro-
cessing. For instance, if different mappers are used, or
if quality scores are calibrated differently, then the pre-
dictions may be less accurate. In addition, it may not be
appropriate to use a carcinogen-driven tumor like lung
cancer to predict somatic mutations in pediatric cancer,
because the mutation profiles of those two types of can-
cers are vastly different. We have tested the performance
of SomaticSeq with a small subset of the data (i.e., a ran-
dom sampling that includes 10–1000 true somatic muta-
tions), and have presented the results in Additional file 1:
Tables S18 and S19, and Additional file 1: Figs. S5 and S6,
for somatic SNVs and indels, respectively. Unsurprisingly,
the accuracy improves with increasing number of data
points in the training set, with diminishing returns after
the training set reaches around 100–200 true somatic
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mutations. However, improvements over individual tools
are shown with just 10–20 true mutations in the training
set. However, in the absence of such a training set, a syn-
thetic data set with characteristics close enough to the
target set would also suffice, as we have done for COLO-
829 and CLL1 with the DREAM Challenge Stage 3 for
training. In this study, we calculate the accuracy of Somat-
icSeq’s predictions based on the known ground truth for
synthetic data (i.e., DREAM Challenge, in silico titration,
and SomaticSpike) and published lists of mutations for
real data (Fig. 10).
In silico titration
We mixed two human genomes (NA12878 and NS12911)
in silico to create a virtual tumor–normal sequencing
experiment as illustrated in Fig. 4. To create any mix-
ture of the two genomes, the two BAM files were ran-
domly downsampled at the appropriate fraction, and then
merged together using Picard tools. To construct the
ground truth from the in silico experiment, if a location
is a homozygous reference in NA12878 (designated nor-
mal) and heterozygous in NS12911 (designated tumor),
this location was considered to be a somatic mutation.
If the site is a homozygous reference in both genomes,
it was considered a reference, so any somatic call that
fell in those regions was considered a false positive. All
other genotyping possibilities were considered ambiguous
for somatic analysis, and were ignored in the downstream
analysis. The schematic to build the ground truth is illus-
trated in Fig. 5. One major difference between our in silico
titration and SomaticSpike is that we used two entirely dif-
ferent genomes as the tumor and normal, whereas Somat-
icSpike used the same genome for both, but selectively
spiked in alternate reads from a different genome as vir-
tual mutations. Our in silico titration was not only able to
capture sequencing artifacts associated with sequencers,
but it also captured artifacts associated with two sepa-
rate sample preparations as would be expected from some
tumor and normal studies.
To obtain the highest confidence truth set, heterozygous
variant calls in NS12911 must be agreed upon by three
germline callers: HaplotypeCaller, FreeBayes, and SAM-
tools. In addition, we only considered the high-confidence
callable regions (minimum depth of 10, minimum map-
ping quality of 20, and minimum base quality of 10) in
both NA12878 and NA12911 for this exercise.
On average, there is at least one single-nucleotide poly-
morphism per 1000 bp in a human genome, and this in
silico titration created over 810,000 virtual somatic muta-
tions, which presented a prior somatic mutation rate of
about one out of 2700. This was orders of magnitudemore
frequent than the “rule of thumb” of one somatic muta-
tion out of every million base pairs [31]. Thus, using all
810,000 virtual somatic mutations would be a poor evalu-
ator of a somatic caller’s precision because true hits would
unrealistically outnumber false positives. It was necessary
to enforce a realistic somatic mutation rate to evaluate
better the precision of each tool in real cancer analysis.
Therefore, 2218 somatic SNVs and indels were randomly
chosen, while the remainder were masked from our anal-
ysis. In SomaticSpike, where we investigated SomaticSeq’s
performance as a function of sequencing depth and VAF,
we randomly chose 3000 somatic SNVs to enforce a one
in a million prior mutation probability. We also refrained
from using dbSNP or COSMIC membership as features
for the in silico experiments, because their membership
statuses in these databases did not reflect the reality in real
cancers. In other words, the results for the in silico titra-
tion presented in this study did not take information from
any prior knowledge.
In in silico titration, we created impure tumors by mix-
ing tumor and normal sequencing reads. Some of the
reads in the virtual impure tumor were identical to reads
in the normal, without expected experimental artifacts
because the normal contamination in this case did not
come from normal tissues, but directly from the normal
data. This led to an inflated precision since identical reads
cannot “fool” the caller. Therefore, to obtain a realistic
Fig. 10Machine learning: a training set with ground truth is provided to the machine-learning algorithm to create an adaptively boosted classifier.
The classifier is applied to a target set to create a high-confidence somatic mutation call set. The call set is compared to the ground truth or the
validated mutation list of the target set to calculate the accuracy (only sensitivity is calculated for real data)
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number of false positives, we used the false positives
obtained from pure normal/pure tumor analysis as false
positives for all in silico analyses. In SomaticSpike, a sep-
arate tumor/normal whole genome analysis was done for
every sequencing depth, and false positives from that were
used for every VAF study of that sequencing depth.
Functional annotation
SNVs reported by SomaticSeq were annotated with
CADD rank scores in dbNSFP v2.8, where the scores were
provided for every non-synonymous SNV. Rank score is a
ratio of the rank of the raw score over the total number
of raw scores in dbNSFP. Larger values indicate relatively
higher deleteriousness. The Wilcoxon rank-sum test was
conducted using pairwise.wilcox.test in R with
multiple testing corrections using the Holm–Bonferroni
method (see Fig. 9). All SNVs reported by SomaticSeq
were also annotated with raw CADD scores generated
using CADD v1.2 and the raw scores were converted to
rank scores (see Additional file 1: Fig. S7).
Additional file
Additional file 1: Supplementary text. It contains detailed results of our
analyses in Figures S1–S7 and Tables S1–S19. It also describes the
location of the data used in this paper. (PDF 531 kb)
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